Gsk Share Discussion Threads

[bull19] 09/2/2022 11:27

Dividends this year were 19+19+19+23=80p. 80/1622 =4.9%Next year totally different due to split

[charlie9038] 09/2/2022 11:21

1.418 x 4 =5.672%

[patientcapital] 09/2/2022 11:09

23/1622x100=1.418%

[charlie9038] 09/2/2022 10:57

divi 23p per share=6.7% if my sums are right

or on todays figure £16.22= 5.6%

Plus capital growth Better than any bank

[semper vigilans] 09/2/2022 10:42

The boss is on Ian King at the moment: is she reading all off an idiot board above her camera? All a bit too shouty for me.

[spoole5] 09/2/2022 10:21

Yep self interest. Should have bitten their hands off. They won't get another offer

[nk104] 09/2/2022 10:21

It just shows that in turning down the 50bn the board were just thinking of their own future prospects rather than running the business in the interests of the shareholders.

It's a similar thing with MNZS this morning - who do the board think they are running the company for?

[tradermichael] 09/2/2022 09:47

Spacecake - 3% would be good for a new CH company saddled with GSK debt!

[pcok] 09/2/2022 09:14

Well done Emma. Solid results and gearing up for an exciting year.

[spacecake] 09/2/2022 09:11

3p dividend for the future consumer business, but whats the yield ?
Will the new shares float at 100p ~ 3% yield

[florenceorbis] 09/2/2022 08:56

British pharmaceutical giant GlaxoSmithKline PLC on Wednesday posted an increase in net profit and sales for the final quarter of 2021.

The company said net profit was 749 million pounds ($1.01 billion) for the fourth quarter, up from GBP677 million for the same period the previous year, on sales that grew to GBP9.53 billion from GBP8.74 billion.

While sales beat expectations, net profit came short of a company-provided consensus, which saw the metric at GBP1.19 billion.

Earnings per share grew to 14.7 pence from 13.6 pence, while adjusted earnings per share--a closely-watched metric that strips off some one-off items--came to 25.6 pence, beating consensus expectations of 23.8 pence.

The company declared a dividend of 23 pence for the fourth quarter and of 80 pence for 2021, in line with what the company had previously said.

Sales in the pharmaceuticals business grew on year in the fourth quarter, driven by growth in the new and specialty products section, Glaxo said.

Vaccine sales, however, took a hit from lower meningitis and shingles shot sales, coming in 7% lower than in the previous year, the company said.

Turnover in the consumer healthcare business rose in the quarter, the company said.

Glaxo said it expects to deliver sales growth in 2022 of between 5% to 7% at constant exchange rates. Adjusted operating profit is expected to grow between 12% and 14% at constant exchange rates during the year, including some anticipated benefit in royalty income from the Gilead settlement.

Glaxo's vaccines business, which includes growth-driving shingles jab Shingrix, is expected to see sales growth in a low-teens percentage at constant exchange rates for the year.

However, the company warned that governments' prioritization of Covid-19 vaccination programs as well as measures to curb the pandemic are going to continue disrupting adult vaccinations, and that it expects the impact of this to be felt in the first half of the year. It still expects Shingrix to deliver double-digit growth with strong demand in both existing and new markets, Glaxo said.

Glaxo said it expects its Covid-19 solutions business to contribute to 2022 sales in a similar proportion to what it did in 2021. However, it foresees a substantially reduced profit contribution from the business, due to the increased sales proportion of lower-margin Covid-19 drug Xevudy.

Glaxo said it continues to expect the demerger of its consumer healthcare business to happen in mid-2022, and that it will give more information on this during its capital markets day on Feb 28.



Write to Cecilia Butini at [e-mail]



(END) Dow Jones Newswires

February 09, 2022 03:31 ET (08:31 GMT)

[berny3] 09/2/2022 07:58

Here is the guidance on dividends: "Quarterly dividends
The Board has declared a fourth interim dividend for 2021 of 23 pence
per share (Q4 2020: 23 pence per share).
On 23 June 2021, at the new GSK Investor Update, GSK set out that
from 2022 a progressive dividend policy will be implemented. The
dividend policy, the total expected cash distribution, and the respective
dividend pay-out ratios for new GSK and new Consumer Healthcare remain
unchanged.
GSK expects to declare a 27p per share dividend payable by the current
group for the first half. This comprises 22 pence per share for new
GSK and 5 pence per share representing Consumer Healthcare during
the first half whilst part of the group. For the second half of 2022,
new GSK continues to expect to declare a 22p per share dividend.
As previously communicated, new GSK would expect to declare a dividend
of 45 pence per share for 2023.
Following separation, the dividend policy for the new Consumer Healthcare
company will be the responsibility of its Board of Directors and
is expected to be guided by a 30 to 50 per cent pay-out ratio. On
this basis, we now expect a second-half dividend from the new Consumer
Healthcare company equivalent to a payout of around 3 pence per share,
subject to its Board's decisions on the intra-year phasing of dividend
payments. This expected distribution per share for the second half
of the year has been adjusted from that highlighted at the GSK Investor
Update in June 2021 to reflect the total number of shares (up to
circa 9.25 billion shares) in the new Consumer Healthcare company
that are expected to be in issue upon demerger. In June 2021 the
planning assumption for the Investor Update reflected only the GSK
shares in issue at that time (circa 5 billion shares).
In aggregate, this would represent on the full year 2022 basis the
equivalent of a Group dividend of around 52p per share. Dividends
payable by Consumer Healthcare will only be receivable by shareholders
who remain invested in Consumer Healthcare post-separation and at
the appropriate record dates.
Payment of dividends"

[spyder] 09/2/2022 07:51

I think the Board will be very much on the back foot at the Q&A this afternoon.
They will need to explain why they think Consumer is worth >£50bn, I suspect we will get a Borisesque “wait until the Investor Day, we will explain further then” answer, which will be very unsatisfactory.
Personally, I’m back to thinking that both parts should be sold off and we let someone else have a go at running this business.
Come on Elliott - time to step up and finish the job!

[maxplus2] 09/2/2022 07:49

Dividend of 23p declared for Q4 2021

[spyder] 09/2/2022 07:44

Solid results but no fireworks.
Does this statement reflect a previous mistake?
“ On this basis, we now expect a second-half dividend from the new Consumer Healthcare company equivalent to a payout of around 3 pence per share, subject to its Board's decisions on the intra-year phasing of dividend payments. This expected distribution per share for the second half of the year has been adjusted from that highlighted at the GSK Investor Update in June 2021 to reflect the total number of shares (up to circa 9.25 billion shares) in the new Consumer Healthcare company that are expected to be in issue upon demerger. In June 2021 the planning assumption for the Investor Update reflected only the GSK shares in issue at that time (circa 5 billion shares).”

[spoole5] 09/2/2022 07:17

Should have taken the 50bn.

[careful] 09/2/2022 07:17

underwhelmed

[eaaxs06] 08/2/2022 20:23

It’s a bit worrying when Glaxo don’t even know what year we’re in at present! It doesn’t bode too well for the announcement of annual figures tomorrow.

Good luck everyone, Sid.

[patientcapital] 08/2/2022 18:22

Quite. There was a self explanatory release over the weekend that news broke. No need to say anything further on the matter. What we do need to know is the timetable for the demerger.

[jonjoneil] 08/2/2022 16:08

wouldn't expect her to even mention it. Most people already know why it was rejected.

[spoole5] 08/2/2022 15:03

Hopefully Emma will have some justification to reject 50bn.

[tradermichael] 07/2/2022 15:46

Well done - it is 24 Feb (I have mistakenly spread fake news. I hope I haven't bought back too early!))

[montedawnster] 07/2/2022 15:23

Ex div is 24th feb. Fact.